DelveInsight’s report titled “Idiopathic Pulmonary Fibrosis Market Insights, Epidemiology, and Market Forecast – 2034” report delivers an in-depth understanding of burns, historical and forecasted epidemiology, as well as the Idiopathic Pulmonary Fibrosis therapeutics market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Unlock key insights into the Idiopathic Pulmonary Fibrosis Market! Download DelveInsight’s comprehensive report to explore market trends, pipeline analysis, and emerging therapies @ Idiopathic Pulmonary Fibrosis Therapeutics Market Outlook

Key Takeaways from the Idiopathic Pulmonary Fibrosis Market Report

• In April 2025, Tvardi Therapeutics announced a study is to evaluate the safety and tolerability of oral daily administration of TTI-101 over a 12-week treatment duration in participants with idiopathic pulmonary fibrosis (IPF).
• In April 2025, GlaxoSmithKline announced a study will assess the safety and effectiveness of GSK3915393 in IPF participants. Idiopathic Pulmonary Fibrosis is a chronic lung disease which causes scarring of the lungs and difficulty in breathing. GSK3915393 is a new medicine, which is being tested in participants with IPF for the first time.
• In April 2025, Boehringer Ingelheim announced a study is open to adults 40 years or older with idiopathic pulmonary fibrosis (IPF). People can join the study if they are not on any treatment for IPF are on stable treatment for at least 3 months before starting the study. The purpose of this study is to find out whether a medicine called BI 1819479 helps people with IPF. 3 different doses of BI 1819479 are tested in this study.
• According to DevelInsight analysis, the estimated total diagnosed prevalent cases of Idiopathic Pulmonary Fibrosis in the 7MM were approximately 193,000 in 2023; this number is expected to increase in the future due to aging populations and improved diagnostic techniques.
• In 2023, among the 7MM, the US accounted for the highest diagnosed prevalent cases of Idiopathic Pulmonary Fibrosis with approximately 95,000 cases. These cases are expected to increase during the forecast period (2024-2034).
• Among the EU4 and the UK, Germany had the highest diagnosed prevalent cases of Idiopathic Pulmonary Fibrosis with nearly 21,000 cases, followed by the UK, and France with approximately 15,700, and 15,500 diagnosed prevalent cases respectively.
• In 2023, the prevalence of idiopathic pulmonary fibrosis in the 7MM was distributed as follows: mild (FVC >75%) with 55,926 cases, moderate (FVC 50%-75%) with 96,424 cases, and severe (FVC <50%) with 40,498 cases. This data underscores the significant number of patients in the moderate stage, indicating a critical need for effective management strategies.
• In the epidemiological model of Idiopathic Pulmonary Fibrosis, cases in the 7MM for 2023 are categorized into age groups with 6,573 cases in the 18-39 years group, 24,492 in the 40-59 years group, 113,411 in the 60-79 years group, and 48,368 in those over 80 years, indicating a significant increase in prevalence with age.
• In 2023, gender-specific diagnosed prevalent cases of Idiopathic Pulmonary Fibrosis in the 7MM were higher in males, with approximately 120,718 cases, compared to females, who had around 73,152 cases, reflecting a higher prevalence in the male population.
• The leading Idiopathic Pulmonary Fibrosis Companies such as FibroGen, Hoffmann-La Roche Ltd, United Therapeutics, Boehringer Ingelheim, Pliant Therapeutics, Inc., Galecto Biotech, Horizon Therapeutics, CSL Behring, Kadmon Corporation, LLCs, MediciNova, PureTech, Bristol-Myers Squibb, Nitto Denko Corporation, Vicore Pharma AB and others.
• Promising Idiopathic Pulmonary Fibrosis Pipeline Therapies such as Pirfenidone, Deupirfenidone, SC1011, TTI-101, Pamrevlumab, PLN-74809, GSK3915393, BMS-986278, Taladegib, and others.

Stay ahead in the competitive landscape of the Idiopathic Pulmonary Fibrosis Market. Access DelveInsight’s in-depth market analysis and strategic insights today! Click here for more @ Idiopathic Pulmonary Fibrosis Treatment Market Size

Idiopathic Pulmonary Fibrosis Epidemiology Segmentation in the 7MM

• Total Idiopathic Pulmonary Fibrosis Diagnosed Prevalent Cases
• Idiopathic Pulmonary Fibrosis Gender- specific Diagnosed Prevalent Cases
• Idiopathic Pulmonary Fibrosis Age-specific Diagnosed Prevalent Cases
• Idiopathic Pulmonary Fibrosis Severity-specific Diagnosed Prevalent Cases

Download the report to understand which factors are driving Idiopathic Pulmonary Fibrosis epidemiology trends @ Idiopathic Pulmonary Fibrosis Prevalence

Idiopathic Pulmonary Fibrosis Marketed Drugs

• OFEV (Nintedanib): Boehringer Ingelheim Pharma GmbH

OFEV is a prescription drug for the treatment of IPF in adults. Nintedanib is the key ingredient and is a kinase inhibitor that inhibits multiple receptor tyrosine kinases (RTKs) and non-receptor tyrosine kinases (nRTKs). Nintedanib is a small molecule that inhibits multiple receptor tyrosine kinases (RTKs) and non-receptor tyrosine kinases (nRTKs). Nintedanib inhibits the following RTKs: platelet-derived growth factor receptor (PDGFR) a and ß, fibroblast growth factor receptor (FGFR) 1-3, vascular endothelial growth factor receptor (VEGFR) 1-3, and Fms-like tyrosine kinase-3 (FLT3).

Idiopathic Pulmonary Fibrosis Emerging Drugs

• BI 1015550: Boehringer Ingelheim

BI 1015550 is an investigational, oral phosphodiesterase 4B (PDE4B) inhibitor with combined antifibrotic and anti-inflammatory effects developed by Boehringer Ingelheim. BI 1015550 was studied as a monotherapy or in combination with background antifibrotic therapy to assess the effectiveness of slowing the rate of lung function decline in patients with Idiopathic Pulmonary Fibrosis. The accelerated development of BI 1015550 is part of Boehringer Ingelheim’s next wave of potential innovative treatments for interstitial lung diseases aimed at preserving lung function and improving the lives of patients.

To learn more about Idiopathic Pulmonary Fibrosis Treatment guidelines, visit @ Idiopathic Pulmonary Fibrosis Market Drivers and Barriers

Idiopathic Pulmonary Fibrosis Drugs Market Insights

The main aim of treatment is to relieve the symptoms as much as possible and slow down its progression. There are two medicines that can help slow down the progression of idiopathic pulmonary fibrosis in people: ESBRIET (Pirfenidone) and OFEV (Nintedanib). Both drugs have shown to slow the disease progression but not significantly impact mortality. For this reason, early initiation of therapy is recommended. Further studies also shown decreased exacerbations of idiopathic pulmonary fibrosis with these drugs. Serial monitoring of liver function tests is recommended while on either drug. The most common side effect reported with Nintedanib is diarrhea and with pirfenidone rash, photosensitivity, and gastrointestinal discomfort. Gastrointestinal side effects are the most common reason for discontinuing both drugs.

Idiopathic Pulmonary Fibrosis Market Outlook

There are two antifibrotic agents approved for use in idiopathic pulmonary fibrosis. These are Pirfenidone and Nintedanib (tyrosine kinase inhibitors). Both drugs are known to slow the disease progression but not significantly impact mortality. For this reason, early initiation of therapy is recommended. Further studies have also decreased exacerbations of idiopathic pulmonary fibrosis with these drugs. Serial monitoring of liver function tests is recommended while on either drug. The most common side effect reported with Nintedanib is diarrhea and pirfenidone rash, photosensitivity, and gastrointestinal discomfort.

Explore the dynamics of the Idiopathic Pulmonary Fibrosis Market with DelveInsight. From market size to emerging drugs-find it all in our latest report. Read now! @ Idiopathic Pulmonary Fibrosis Ongoing Clinical Trials Analysis

Scope of the Idiopathic Pulmonary Fibrosis Market Report

• Coverage- 7MM
• Study Period- 2020-2034
• Idiopathic Pulmonary Fibrosis Companies- FibroGen, Hoffmann-La Roche Ltd, United Therapeutics, Boehringer Ingelheim, Pliant Therapeutics, Inc., Galecto Biotech, Horizon Therapeutics, CSL Behring, Kadmon Corporation, LLCs, MediciNova, PureTech, Bristol-Myers Squibb, Nitto Denko Corporation, Vicore Pharma AB and others.
• Idiopathic Pulmonary Fibrosis Pipeline Therapies- Pirfenidone, Deupirfenidone, SC1011, TTI-101, Pamrevlumab, PLN-74809, GSK3915393, BMS-986278, Taladegib, and others.
• Idiopathic Pulmonary Fibrosis Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
• Idiopathic Pulmonary Fibrosis Unmet Needs, KOL’s views, Analyst’s views, Idiopathic Pulmonary Fibrosis Market Access and Reimbursement

Table of Content

1 Key Insights

2 Report Introduction

3 Idiopathic Pulmonary Fibrosis (IPF) Market Overview at a Glance

4 Idiopathic Pulmonary Fibrosis Epidemiology and Market Forecast Methodology

5 Key Events

6 Idiopathic Pulmonary Fibrosis Executive Summary

7 Idiopathic Pulmonary Fibrosis Market Disease Background and Overview

8 Idiopathic Pulmonary Fibrosis Epidemiology and Patient Population

9 Idiopathic Pulmonary Fibrosis Patient Journey

10 Idiopathic Pulmonary Fibrosis Marketed Drugs

11 Idiopathic Pulmonary Fibrosis Emerging Drugs

12 Idiopathic Pulmonary Fibrosis: Seven Major Market Analysis

13 Idiopathic Pulmonary Fibrosis KOL Views

14 Idiopathic Pulmonary Fibrosis SWOT Analysis

15 Idiopathic Pulmonary Fibrosis Unmet needs

16 Idiopathic Pulmonary Fibrosis Market Access and Reimbursement

17 Appendix

18 Report Methodology

19 DelveInsight Capabilities

20 Disclaimer

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/idiopathic-pulmonary-fibrosis-market